Permethrin Baby Wraps: Malaria Prevention
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- This finding primarily impacts individuals who already have established cardiovascular disease - meaning a prior heart attack, stroke, or peripheral artery disease - *and* obesity.
Ozempic adn Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated notable weight loss, the cardiovascular safety signal is prompting a reassessment of its use in this specific patient population.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. However, it’s crucial to note that the absolute risk difference was relatively small – 1.6% – meaning that for every 100 patients treated with semaglutide, approximately 1.6 additional cardiovascular events occurred.
| Outcome | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 3.7 | 2.6 |
| Non-Fatal stroke | 2.8 | 1.9 |
| Non-Fatal Myocardial Infarction (Heart Attack) | 3.4 | 2.4 |
| MACE (Major Adverse Cardiovascular Event) | 6.5 | 4.9 |
Who is Affected? understanding Patient Risk
This finding primarily impacts individuals who already have established cardiovascular disease – meaning a prior heart attack, stroke, or peripheral artery disease – *and* obesity. The trial did *not* include patients with type 2 diabetes, a population where semaglutide has previously demonstrated cardiovascular benefits. Therefore, the results cannot be directly extrapolated to individuals using semaglutide for diabetes management. It’s vital to emphasize that the study doesn’t suggest semaglutide *causes* heart disease, but rather that it may slightly increase the risk of events in those already vulnerable.
Why This Matters: Beyond Weight Loss
Semaglutide, initially developed for diabetes, gained widespread popularity for its dramatic weight loss effects. This led to off-label prescriptions for obesity, ofen with the assumption of cardiovascular safety, or even benefit. The SELECT trial challenges this assumption.The increased risk, while modest, is statistically significant and warrants a careful consideration of the risk-benefit ratio, notably given the availability of other weight loss strategies.
Timeline of Events & Current Recommendations